The small miracles that 2024 brought to our lives lay the groundwork for new revolutionary treatments that are being prepared ...
Investors need to pay close attention to Vertex Pharmaceuticals (VRTX) stock based on the movements in the options market lately.
NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
INR:3164. a wingo way song Sina Pharmaceuticals Live Lesson 3丨The Theoretical System and Practical Essentials of the New GCP Vertex's innovative triple therapy ...
Read about how Crispr's robust pipeline for cardiovascular diseases holds blockbuster potential, with top-line results ...
The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...
Shares of Vertex Pharmaceuticals Inc. VRTX slid 0.46% to $408.76 Friday, on what proved to be an all-around rough trading ...
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
Of the top news articles, Vertex Pharmaceuticals' suzetrigine garnered much attention as it's a promising new class of pain ...
Equities researchers at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Vertex Pharmaceuticals ...
Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...
Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $408.18 which represents a slight increase of $2.91 or 0.72% from the prior close of $405.27. The stock opened at $401.53 ...